Recently, the Shanghai Financial Industry Association, the Shanghai Civil Construction Enterprise Development Promotion Center and a number of inclusive financial advisers from the Industrial and Commercial Bank of China, Agricultural Bank of China, Bank of Communications, Shanghai Bank, Minsheng Bank, China Merchants Bank, Zhejiang Merchants Bank and HSBC came to Yuanvore Medicine in person to provide face-to-face financial advisory services!

The biomedical industry faces special financing challenges because of its long R & D cycle, high professional barriers, large capital investment and high risk. New drugs need to go through a long and complex process from preliminary research and development to clinical trials and finally to market, which makes it difficult for biomedical companies to achieve sales revenue in a short period of time. At the same time, such enterprises often have light assets and huge R & D investment, which makes them more stretched at the financial level, resulting in a unique financing problem for the industry.

Yuanvore Medicine, as a regenerative medicine company focusing on the development and application of iPSC (induced pluripotent Stem Cell) technology, focuses on stem cell drugs in the field of global cutting-edge technology CGT (Cell and Gene Therapy). Therefore, Yuanvore Medicine is under greater financial pressure than conventional pharmaceutical companies in laying out R & D pipelines, purchasing advanced R & D equipment, attracting and training professionals and so on. In the face of these challenges, Yuanvore Medicine needs to seek more effective financing ways and strategies to ensure the smooth progress of research and development, so as to achieve one milestone after another.

The consultants at the meeting pointed out that at present, the credit products of commercial banks are becoming more and more abundant, and in supporting scientific and technological start-up enterprises, the consideration of non-financial factors such as the actual controller of the enterprise, the background of the core R & D team, intellectual property rights, the park to which they belong, and the professional qualifications of the enterprise have been increased, thus breaking the old service model of "loans only look at three tables". In addition, more and more online credit products have achieved quota enhancement and term extension to meet the actual needs of medium-and long-term liquidity of science and technology start-up enterprises.

While putting forward the "brilliant plan out of pocket", the consultants at the meeting introduced the corresponding credit service products on the spot according to the characteristics of their own financial institutions, accurately docking the needs of enterprise operation and development.

【Yuanvore Heartfelt voice】

As an entrepreneur, what is the experience of "offline consultation" by more than a dozen financial experts and advisers from 8 banks? Ouyangping, founder of Yuanvore Medicine, replied: this is a two-way trip of "finance" and "science and technology". He is deeply moved and firmly believes once again that it is right to choose to start a business in Shanghai! The inclusive financial advisory system launched by the Shanghai Financial Industry Association has enabled countless mass entrepreneurship and innovation enterprises in financial difficulties such as Yuanvore Medicine to get through the first kilometer of docking financial services. 

With the blessing of financial power, we have more courage to realize our dreams and create miracles. The coordination of multiple institutions, the docking of targeted financial services and the companionship of the whole life cycle are all the highlights of the big article "Science and Technology Finance" written in Shanghai. 

Finally, Yuanvore Medicine team is once again grateful for this era, thanks to the Shanghai Banking Industry and Shanghai Civil Construction Enterprise Service Center for their exploration and efforts to support scientific and technological innovation. We will live up to high expectations and be innovation-oriented. To create a global biomedical innovation highland for Shanghai.